成人及老年人多病共存与多重用药患病率的系统综述
该系统综述检索六个电子数据库,最终纳入87项研究,考察成人(≥18岁)和老年人(≥65岁)在临床与社区环境中多病共存和多重用药的患病率。多数研究聚焦65岁及以上人群且基于人群社区环境,尽管操作定义各异,多数研究采用一致切点(≥2种疾病和≥5种药物)。
要点
- 多数研究采用≥2种疾病定义多病共存、≥5种药物定义多重用药。
- 研究间高度异质性提示需统一报告操作定义中的疾病与药物清单。
核心结论
- 多病共存与多重用药在成人及老年人中患病率范围宽泛,研究间高度异质性提示需更一致地报告操作定义中的具体疾病和药物清单。
研究设计与样本
- 系统综述检索六个电子数据库,经两级筛选后纳入87项研究,覆盖成人(≥18岁)和老年人(≥65岁)的临床与社区环境。
主要发现
- 多数研究聚焦65岁及以上人群且基于人群社区环境。
关键数值与推荐
- 多数研究采用多病共存切点为两种或以上疾病。
- 多数研究采用多重用药切点为五种或以上药物。
临床怎么用
- 老年医学科医生应关注多病共存与多重用药的共现评估,结合本地人群特征解读患病率范围。
- 在临床记录中宜明确列出具体疾病和药物清单,以促进操作定义的一致性。
局限性
- 多病共存和多重用药的操作定义在研究间存在差异。
- 研究间高度异质性限制患病率范围的合并解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multimorbidity (multiple conditions) and polypharmacy (multiple medications) are increasingly common, yet there is a need to better understand the prevalence of co-occurrence. In this systematic review, we examined the prevalence of multimorbidity and polypharmacy among adults (≥18 years) and older adults (≥65 years) in clinical and community settings. Six electronic databases were searched, and 87 studies were retained after two levels of screening. Most studies focused on adults 65 years and older and were done in population-based community settings. Although the operational definitions of multimorbidity and polypharmacy varied across studies, consistent cut-points (two or more conditions and five or more medications) were used across most studies. In older adult samples, the prevalence of multimorbidity ranged from 4·8% to 93·1%, while the prevalence of polypharmacy ranged from 2·6% to 86·6%. High heterogeneity between studies indicates the need for more consistent reporting of specific lists of conditions and medications used in operational definitions.
引用
- Nicholson K, Liu W, Fitzpatrick D, et al. Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review. Lancet Healthy Longev. 2024. PMID: 38452787. doi:10.1016/S2666-7568(24)00007-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。